Expert InterviewCMPX
Slingshot members are talking to an expert! The topic is:
Examining the Phase 2/3 COMPANION-002 trial results for Tovecimig (CTX-009) in second-line Biliary Tract Cancer from Compass Therapeutics
Executed on:Apr 29, 2026 1:00 PM EDT
Call Duration:30 minutes
Expert Profile
ExpertBlinded Expert
Institution: Advanced Care Oncology And Hematology Associates
- Medical Oncologist & Partner at ACOHA (private practice in New Jersey); fellowship trained at New York Presbyterian-Columbia University Medical Center.
- Manages 400 patients with solid tumors and 25 patients with gastroesophageal junction cancer.
- Lectures widely on Gastrointestinal, Genitourinary and breast malignancies.
Interview Goal
This interview will examine the top-line findings from the Phase 2/3 COMPANION-002 trial evaluating tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody, in combination with paclitaxel in second-line biliary tract cancer (BTC). The conversation will highlight the clinical relevance of the confirmed response rate difference, potential implications of improved disease control, and expectations for the forthcoming analyses of secondary endpoints. Additional discussion will address trial design, unmet needs in BTC, and the significance of having a treatment option in a setting with no FDA-approved therapies.